R96
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.290
- ALLOGRAFT_REJECTION+0.270
- MYOGENESIS+0.200
- INFLAMMATORY_RESPONSE+0.190
- PANCREAS_BETA_CELLS+0.190
- IL6_JAK_STAT3_SIGNALING+0.170
- APICAL_SURFACE+0.140
- SPERMATOGENESIS+0.140
- APICAL_JUNCTION+0.070
- IL2_STAT5_SIGNALING+0.040
Top 10 suppressed
- PROTEIN_SECRETION-0.680
- MYC_TARGETS_V1-0.550
- MTORC1_SIGNALING-0.440
- OXIDATIVE_PHOSPHORYLATION-0.440
- ANDROGEN_RESPONSE-0.430
- UNFOLDED_PROTEIN_RESPONSE-0.410
- UV_RESPONSE_DN-0.390
- ADIPOGENESIS-0.380
- FATTY_ACID_METABOLISM-0.350
- E2F_TARGETS-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0123 | Med | Medulloblastoma | 0.928 |
| 2 | MNG1098 | — | — | 0.920 |
| 3 | MNG1159 | — | — | 0.914 |
| 4 | MDT-AP-1143 | Med | Medulloblastoma | 0.908 |
| 5 | SJEPD031_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.905 |
| 6 | MNG1245 | — | — | 0.901 |
| 7 | BS_TCGEZJ5F | EPN | Supratentorial EPN | 0.901 |
| 8 | SRR1337431 | GTEX | — | 0.898 |
| 9 | MNG441 | — | — | 0.893 |
| 10 | SJEPD014_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.892 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.170 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.070 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.040 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.040 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.020 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.010 | Inavolisib | — uncovered |